A surrogate cell-based SARS-CoV-2 spike blocking assay.
Eur J Immunol
; 51(11): 2665-2676, 2021 11.
Article
in English
| MEDLINE | ID: covidwho-1482126
ABSTRACT
To monitor infection by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and successful vaccination against coronavirus disease 2019 (COVID-19), the kinetics of neutralizing or blocking anti-SARS-CoV-2 antibody titers need to be assessed. Here, we report the development of a quick and inexpensive surrogate SARS-CoV-2 blocking assay (SUBA) using immobilized recombinant human angiotensin-converting enzyme 2 (hACE2) and human cells expressing the native form of surface SARS-CoV-2 spike protein. Spike protein-expressing cells bound to hACE2 in the absence or presence of blocking antibodies were quantified by measuring the optical density of cell-associated crystal violet in a spectrophotometer. The advantages are that SUBA is a fast and inexpensive assay, which does not require biosafety level 2- or 3-approved laboratories. Most importantly, SUBA detects blocking antibodies against the native trimeric cell-bound SARS-CoV-2 spike protein and can be rapidly adjusted to quickly pre-screen already approved therapeutic antibodies or sera from vaccinated individuals for their ACE2 blocking activities against any emerging SARS-CoV-2 variants.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Antibodies, Blocking
/
Antibodies, Neutralizing
/
Flow Cytometry
/
COVID-19 Serological Testing
/
COVID-19
/
Antibodies, Viral
Type of study:
Diagnostic study
Topics:
Vaccines
/
Variants
Limits:
Humans
Language:
English
Journal:
Eur J Immunol
Year:
2021
Document Type:
Article
Affiliation country:
Eji.202149302
Similar
MEDLINE
...
LILACS
LIS